natgillin/translations-raw huggingface dataset:
The following are all the ADRs that were reported in clinical trials and postmarketing experience with paliperidone by frequency category estimated from INVEGA clinical trials in adults.
U daljnjem tekstu navedene su sve nuspojave prijavljene u kliničkim ispitivanjima i nakon stavljanja lijeka u promet paliperidona prema kategoriji učestalosti iz kliničkih ispitivanja lijeka INVEGA u odraslih.
The following are precautions for use of Osigraft to be discussed with your doctor.
U nastavku slijede mjere opreza za primjenu Osigrafta koje treba razmotriti s liječnikom.
The following are reasons why Cymbalta may not be suitable for you.
U nastavku su naveden razlozi zbog kojih Cymbalta možda nije prikladna za Vas.
The following are reasons why Duloxetine Lilly may not be suitable for you.
U nastavku su naveden razlozi zbog kojih Duloksetin Lilly možda nije prikladna za Vas.
The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, , atrial fibrillation, anaphylaxis , interstitial lung disease.
Utvrđeni su sljedeći važni rizici primanja zoledronatne kiseline u odobrenim indikacijama: oštećenje funkcije bubrega, osteonekroza čeljusti, reakcija akutne faze, hipokalcemija, fibrilacija atrija, anafilaksija, intersticijska bolest pluća.
The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, ocular adverse events, atrial fibrillation, anaphylaxis.
Utvrđeni su sljedeći važni rizici primanja zoledronatne kiseline u odobrenim indikacijama: oštećenje funkcije bubrega, osteonekroza čeljusti, reakcija akutne faze, hipokalcemija, očne nuspojave, fibrilacija atrija i anafilaksija.
The following can all be signs of serious side effects:
Sljedeće mogu biti znakovi ozbiljnih nuspojava:
The following can be considered to be examples of effective methods of contraception:
Sljedeće metode kontracepcije mogu se smatrati djelotvornima:
The following categories are used to rank the adverse reactions by frequency of occurrence: very common ( ≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); and very rare (<1/10,000), including isolated reports.
S obzirom na učestalost javljanja, nuspojave su razvrstane po slijedećim kategorijama: vrlo čest≥e 1(/10); česte (≥1/100 i < 1/10); manje česte (≥1/1.000 i <1/100); rijetke (≥ 1/10.000 i <1.000) i vrlo rijetke (<1/10.000) uključujući pojedinačne slučajeve.
The following categories are used to rank the adverse reactions by frequency of occurrence: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
Sljedeće kategorije korištene su za svrstavanje nuspojava prema učestalosti pojavljivanja: vrlo često (≥ 1/10); često (≥ 1/100 do < 1/10); manje često (≥ 1/1000 do < 1/100); rijetko (≥ 1/10 000 do
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):
Sljedeće promjene, zabilježene kod štakora i makaki majmuna koji su dobivali kombinaciju irbesartan/hidroklorotiazid u dozama od 10/10 i 90/90 mg/kg/dan, također su uočene i kod pojedinačne primjene ovih lijekova i/ili su bile sekundarne sniženju krvnog tlaka (nisu zabilježene značajne toksikološke interakcije):
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):
Sljedeće promjene, zabilježene kod štakora i makaki majmuna, koji su dobivali kombinaciju irbesartan/hidroklorotiazid u dozama od 10/10 i 90/90 mg/kg/dan, također su uočene i kod pojedinačne primjene ovih lijekova i/ili su bile sekundarne sniženju krvnog tlaka (nisu zabilježene značajne toksikološke interakcije):
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):
Sljedeće promjene, zabilježene u štakora i makaki majmuna, koji su dobivali kombinaciju irbesartan/hidroklorotiazid u dozama od 10/10 i 90/90 mg/kg/dan, također su uočene i kod pojedinačne primjene ovih lijekova i/ili su bile sekundarne sniženju krvnog tlaka (nisu zabilježene značajne toksikološke interakcije):
The following clinical safety features (hepatotoxicity, hyperlipidaemia, bleeding events, rash) were seen at higher frequency among tipranavir with ritonavir treated patients when compared with the comparator arm treated patients in the RESIST trials, or have been observed with tipranavir with ritonavir administration.
Sljedeća obilježja kliničke sigurnosti (hepatotoksičnost, hiperlipidemija, epizode krvarenja, osip) primijećena su s većom učestalošću među bolesnicima liječenim tipranavirom s ritonavirom u usporedbi s bolesnicima u kontrolnoj skupini u ispitivanju RESIST, ili su primijećena u primjeni tipranavira s ritonavirom.
The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, but the evidence of an association with COC use is inconclusive: Jaundice and/or pruritus related to cholestasis; gallbladder disease including cholecystitis and cholelithiasis; porphyria; systemic lupus erythematosus; haemolytic ureamic syndrome; Sydenham’s chorea; herpes gestationis; otosclerosis-related hearing loss.
Navedena stanja ili njihova pogoršanja bila su prijavljena u trudnoći i uz primjenu KOK-a, ali nije moguće izvući uvjerljive dokaze o njihovoj povezanosti s primjenom KOK-a: žutica i/ili svrbež povezani s kolestazom; bolest žučnog mjehura uključujući kolecistitis i kolelitijazu; porfirija; sistemski eritemski lupus; hemolitičko-uremički sindrom; Sydenhamova koreja; gestacijski herpes; gubitak sluha povezan s otosklerozom.
The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, but the evidence of an association with COC use is inconclusive: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham’s chorea; herpes gestationis; otosclerosis-related hearing loss.
Pojava ili pogoršanje sljedećih bolesti prijavljenih u trudnoći i kod primjene KOK-a, no nije definitivno dokazana njihova povezanost s kombiniranim oralnim kontraceptivima: žutica i/ili pruritus povezan s kolestazom; nastanak žučnih kamenaca; porfirija; sistemski lupus eritematodes; hemolitički uremijski sindrom; Sydenhamova koreja; gestacijski herpes; gubitak sluha povezan s otosklerozom.
The following convention has been used for classification of frequency:
Za određivanje učestalosti korištene su sljedeće kategorije:
The following convention has been used for classification of frequency: Very common (1/10)
Za određivanje učestalosti korištene su sljedeće kategorije:
The following convention has been used for the classification of adverse reactions:
Sljedeće dogovorene vrijednosti su korištene za klasifikaciju učestalosti nuspojava:
The following convention has been used for the classification of adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100).
Primijenila se sljedeća konvencija za klasifikaciju nuspojava: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100).
The following convention has been used for the classification of adverse reactions: Very common (1/10)
Za klasifikaciju nuspojava prema učestalosti korištena je sljedeća definicija: Vrlo često (1/10)
The following convention has been used for the classification of frequencies: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Za određivanje učestalosti korištene su sljedeće kategorije: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000); vrlo rijetko (<1/10 000).
The following convention has been used for the classification of frequency:
Za klasifikaciju učestalosti koristila su se sljedeća pravila:
The following convention has been used for the classification of frequency:
Za određivanje učestalosti korištene su sljedeće kategorije:
The following convention has been used for the classification of the adverse reactions (see table 1): very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Sljedeća je razdioba korištena za klasifikaciju nuspojava (vidjeti tablicu 1): vrlo česte ( ≥ 1/10), česte (≥ 1/100 do < 1/10), manje česte (≥ 1/1000 do < 1/100), rijetke (≥ 1/10 000 do < 1/1000) i vrlo rijetke (< 1/10 000).
The following convention has been used for the classification of the adverse reactions based on incidence rates in three phase III and two phase II clinical studies (see table 1): very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Za klasifikaciju nuspojava temeljenih na stopi incidencija u tri klinička ispitivanja faze III i dva klinička ispitivanja faze II (vidjeti tablicu 1) korištena je sljedeća klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1 000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1 000) i vrlo rijetko (< 1/10 000).
The following convention has been used for the classification of the adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Unutar svake grupe učestalost nuspojave klasificirana je na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
The following convention has been used for their classification: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1,000 to <1/100), rare (>1/10,000 to <1/1,000) very rare (<1/10,000).
Klasificirane su prema učestalosti: vrlo često (>1/10), često (>1/100 do <1/10), manje često (>1/1000 do <1/100), rijetko (>1/10 000 do <1/1000), vrlo rijetko (<1/10 000).
The following convention has been utilised for the classification of frequency:
Sljedeće dogovorene vrijednosti korištene su za klasifikaciju učestalosti:
The following convention has been utilised for the classification of frequency:
Sljedeće dogovorene vrijednosti su korištene za klasifikaciju učestalosti:
The following convention has been utilised for the classification of frequency: very common ((1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000) and very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasificirane na sljedeći način: vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1000 do <1/100), rijetko (≥1/10 000 do <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se odrediti iz dostupnih podataka).
The following conventional classification is used: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following conventional classification is used: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following conventional classification is used: very common 1/10), common 1/100 to <1/10), uncommon 1/1,000 to <1/100), rare ( 1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following CTCAE (version 3.0) Grade 3 adverse reactions occurred in patients treated with abiraterone acetate: hypokalaemia 3%; urinary tract infection, alanine aminotransferase increased, hypertension, aspartate aminotransferase increased, fractures 2%; peripheral oedema, cardiac failure, and atrial fibrillation 1% each.
U bolesnika liječenih abirateronacetatom nastupile su sljedeće nuspojave stupnja 3 prema CTCAE (verzija 3.0): hipokalemija u 3%; infekcija mokraćnih puteva, povišena razina alanin aminotransferaze, hipertenzija, povišena razina aspartat aminotransferaze, frakture u 2%; periferni edemi, zatajenje srca i fibrilacija atrija, svaka u 1% bolesnika.
The following data refer to the safety experience of oral CellCept in renal transplant patients.
Sljedeći podaci odnose se na iskustva o praćenju sigurnosti primjene lijeka CellCept kroz usta u bolesnika s presađenim bubregom.
The following definitions apply to the frequency terminology used hereafter:
Učestalost pojavljivanja opisana je sljedećom terminologijom:
The following definitions apply to the frequency terminology used hereafter:
Za opis učestalosti koji se koristi u daljnjem tekstu primjenjuju se sljedeće definicije:
The following definitions apply to the frequency terminology used hereafter: Very common ( 1/10)
Učestalost pojavljivanja opisana je sljedećom terminologijom: Vrlo često ( 1/10)
The following definitions apply to the frequency terminology used hereafter: Very common ≥ 1/10;
Nadalje se primjenjuju sljedeće definicije koje se koriste za opis učestalosti: Vrlo često ≥ 1/10;
The following dosage modifications are recommended during therapy and should be performed in parallel for both Myocet and cyclophosphamide.
Sljedeće izmjene doze preporučuju se tijekom liječenja te ih treba provoditi paralelno s Myocetom i ciklofosfamidom.
The following dosage schedule is suggested for initiation of therapy:
Preporučuje se sljedeća shema doziranja u početku terapije:
The following dose regimens are given as a guideline.
Stoga postoje sljedeće okvirne smjernice o režimu doziranja.
The following doses are recommended: Dogs:
Preporučene su sljedeće doze: Psi:
The following doses are recommended: Dogs:
Preporučuju se sljedeće doze: Psi:
The following dosing regimen is recommended for infants less than 1 year of age:
Za dojenčad mlađu od 1 godine preporučeno je sljedeće doziranje:
The following dosing regimen is recommended for treatment of infants 0 - 12 months of age:
Za liječenje dojenčadi mlađe od 1 godine preporučena su sljedeća doziranja prilagođena dobi:
The following dosing regimen is recommended for treatment of infants 0 - 12 months of age:
Za liječenje dojenčadi u dobi od 0 – 12 mjeseci preporučeno je sljedeće doziranje:
The following dosing schedule is advised: start treatment with 1 tablet (1 mg estriol) every day.
Savjetuje se slijedeći raspored doziranja: započeti s 1 tabletom (1 mg estriola) svaki dan.
The following dosing schedule is advised: start treatment with 1 tablet every day.
Savjetuje se slijedeći raspored doziranja: započeti s 1 tabletom (1 mg estriol) svaki dan.
The following double amino acid substitutions conferred more than 10-fold reduced sensitivity to boceprevir: V55A+I170V, T54S+R155K, R155K+D168N, R155T+D168N and V36M+R155K.
Sljedeće dvostruke aminokiselinske supstitucije smanjile su osjetljivost na boceprevir više od 10 puta: V55A+I170V, T54S+R155K, R155K+D168N, R155T+D168N i V36M+R155K.
The following effects have occurred in children and adolescents:
Sljedeće nuspojave javile su se u djece i adolescenata:
The following endpoints were assessed: normalisation of ALT, decrease in LDL-cholesterol, decrease in non-HDL-cholesterol, normalisation of AST, decrease in triglycerides, increase in HDL- cholesterol, decrease in liver fat content assessed by multi-echo gradient echo magnetic resonance imaging (MEGE-MRI), and improvement in hepatic steatosis measured by morphometry.
Procjenjivane su sljedeće ishodi: normalizacija ALT-a, snižavanje razine LDL kolesterola, snižavanje razine ne-HDL kolesterola, normalizacija AST-a, snižavanje razine triglicerida, porast razine HDL kolesterola, smanjenje količine masti u jetri procijenjeno pomoću MEGE-MR-a (engl. multi-echo gradient echo magnetic resonance imaging, MEGE-MRI) i poboljšanje jetrene steatoze mjereno morfometrijom.
The following events have also been reported when nevirapine has been used in combination with other antiretroviral agents:
Sljedeći slučajevi također su prijavljeni kada se nevirapin primjenjuje u kombinaciji s drugim antiretrovirusnim lijekovima:
The following events have also been reported when Viramune has been used in combination with other antiretroviral agents:
Sljedeći slučajevi također su prijavljeni kada se Viramune primjenjivao u kombinaciji s drugim antiretrovirusnim lijekovima:
The following events have also been reported when Viramune has been used in combination with other antiretroviral agents:
Sljedeći slučajevi također su prijavljeni kada se Viramune primjenjuje u kombinaciji s drugim antiretrovirusnim lijekovima:
The following events have been reported in association with darifenacin use in worldwide post- marketing experience: generalised hypersensitivity reactions including angioedema, depressed mood/mood alterations, hallucination.
Sljedeći događaji su prijavljeni nakon stavljanja darifenacina u promet u cijelom svijetu: generalizirane reakcije preosjetljivosti uključujući angioedem, depresivno raspoloženje/promjene raspoloženja, halucinacija.
The following events have been reported in association with unintended overdoses in preterm neonates: complete atrioventricular block, cardiomyopathy, lactic acidosis, and acute renal failure.
Zabilježeni su sljedeći događaji povezani s nenamjernih predoziranjem kod prijevremeno rođene djece: totalni atrioventrikularni blok, kardiomiopatija, laktocidoza i akutno zatajenje bubrega.
The following examples assume the patient’s baseline factor X level is <1 IU/dL:
Sljedeći primjeri pretpostavljaju da je bolesnikova početna vrijednost razine faktora X < 1 IU/dl:
The following factors were pre- specified in the statistical analysis plan for inclusion in the model: age, time from surgery to randomization, gender, CEA levels at baseline, lymph nodes at baseline, and country.
Sljedeći čimbenici bili su prethodno specificirani u statističkoj analizi uključivanja u model: dob, vrijeme od kirurškog zahvata do randomizacije, spol, početna razina CEA (karcinoembrionalni antigen), status limfnih čvorova na početku i zemlja porijekla.
The following formula can be used to calculate the volume of reconstituted VIBATIV concentrate required to prepare a dose:
Sljedeća formula može se primijeniti za izračunavanje volumena rekonstituiranog koncentrata lijeka VIBATIV potrebnog za pripremu doze:
The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated:
Sljedeće skupine bolesnika s kardio vaskularnom bolešću nisu bile uključene u klinička ispitivanja pa je primjena tadalafila u tim skupinama kontraindicirana:
The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated:
Sljedeće skupine bolesnika s kardiovaskularnom bolešću nisu bile uključene u klinička ispitivanja pa je primjena tadalafila u tim skupinama kontraindicirana:
The following has also been reported: Muscle weakness.
Prijavljeno je i sljedeće: mišićna slabost.
The following headings are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10) uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10) , manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000) i vrlo rijetko (< 1/10 000).
The following headings are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
The following headings are used to rank the ADRs by frequency: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
The following headings are used to rank the ADRs by frequency: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000) i vrlo rijetko (< 1/10 000).
The following immune-related adverse reactions were reported in less than 1% of patients treated with nivolumab monotherapy in clinical trials across doses and tumour types: pancreatitis, uveitis, demyelination, autoimmune neuropathy (including facial and abducens nerve paresis), Guillain-Barré syndrome, hypopituitarism, and myasthenic syndrome.
Sljedeće imunološki uzrokovane nuspojave prijavljene su u manje od 1% bolesnika koji su u kliničkim ispitivanjima primali različite doze nivolumaba u monoterapiji za liječenje različitih vrsta tumora: pankreatitis, uveitis, demijelinizacija, autoimuna neuropatija (uključujući parezu ličnog živca i živca odmicača oka), Guillain-Barréov sindrom, hipopituitarizam i mijastenički sindrom.
The following inclusion criteria were considered for the treatment: patients older than 50 years of age, presence of CNV secondary to AMD, presence of classic lesion components in the CNV (defined as a well-demarcated area of the fluorescence on angiography), CNV located subfoveally (involved the geometric centre of the foveal avascular zone), area of classic plus occult CNV 50% of the total lesion surface, greatest linear dimension of the entire lesion 9 Macular Photocoagulation Study (MPS) disc area, and a best-corrected visual acuity between 34 and 73 letters (i.e. approximately 20/40 and 20/200) in the treated eye.
Kriteriji za uključivanje u ispitivanje bili su sljedeći: dob bolesnika veća od 50 godina, prisutnost CNV-a zbog AMD-a, prisutnost komponenata klasičnih lezija CNV-a (definirano kao dobro ograničeno područje fluorescencije na angiografiji), subfovealna lokalizacija CNV-a (sa zahvaćenim geometrijskim središtem fovealne zone bez vaskulature), zbroj površina klasičnog i prikrivenog CNV-a 50% ukupne površine lezije, najveća linearna dimenzija cijele lezije 9 područja diska u ispitivanju makularne fotokoagulacije (Macular Photocoagulation Study, MPS) i vidna oštrina oka koje se liječi između 34 i 73 znaka (t.j. između 20/40 i 20/200) pri najboljoj mogućoj korekciji.
The following information is based on information about combined birth control pills.
Informacije koje slijede temelje se na podacima o kombiniranim kontracepcijskim tabletama.